Molecular Basis of Cancer

Molecular Basis of Cancer

Molecular Basis of Cancer

On this page

Oncogenes & Growth Signals - Go-Go Growth Genes

  • Oncogenes: Mutated proto-oncogenes; drive uncontrolled cell growth (gain-of-function). "Accelerator ON".
  • Activation:
    • Point mutation: RAS (KRAS, HRAS, NRAS).
    • Amplification: HER2/neu (breast), NMYC (neuroblastoma).
    • Translocation: BCR-ABL (CML), MYC-IgH (Burkitt's).
  • Pathway Hijack:
  • Key Examples by Class:
    • Receptors: EGFR (lung adeno); HER2/neu (ERBB2) (breast, ovary, gastric ca). 📌 "HER 2 much growth".
    • Transducers: RAS (pancreas, colon, lung); BRAF (melanoma); ABL (CML).
    • Nuclear Factors: MYC (Burkitt's, neuroblastoma); drives growth, angiogenesis.

RAS mutations (KRAS, HRAS, NRAS) affect ~15-20% of human cancers; a key oncogene family.

Tumor Suppressors & Genome Guardians - Stop Signs & Fix-It Crew

  • Function: Genes that normally inhibit cell proliferation or promote DNA repair. Loss of function (LOF) → cancer.
    • Knudson's "two-hit" hypothesis: both alleles inactivated for cancer development.
  • Key Examples:
    • RB (Retinoblastoma): "Governor". Controls G1/S checkpoint by binding E2F.
      • Inactive when hyperphosphorylated by CyclinD-CDK4/6.
      • Associated: Retinoblastoma, osteosarcoma.
    • TP53 (p53): "Guardian". Responds to DNA damage.
      • Actions: Cell cycle arrest (via p21), DNA repair, Apoptosis (via BAX).
      • Li-Fraumeni syndrome (germline).
-   **APC**: Degrades β-catenin (WNT pathway). Familial Adenomatous Polyposis (FAP).
-   **BRCA1/BRCA2**: DNA repair (homologous recombination). ↑Breast, ovarian cancer risk.
-   **CDKN2A (p16<sup>INK4a</sup>)**: Inhibits CDK4/6 → keeps RB active.

⭐ TP53 is mutated in >50% of human cancers, leading to genomic instability. Rb loss in retinoblastoma and cancer progression

Epigenetics & Non-Coding RNAs - Silent Gene Tweaks

  • Epigenetics: Heritable gene expression changes without DNA sequence alteration.
    • DNA Methylation:
      • Promoter hypermethylation → silences Tumor Suppressor Genes (TSGs) (e.g., CDKN2A (p16), MLH1).
      • Global hypomethylation → activates oncogenes.
    • Histone Modification: Acetylation (↑activity), deacetylation (↓activity). Dysregulated 'histone code'.
  • Non-Coding RNAs (ncRNAs): Regulatory RNAs; not translated.
    • MicroRNAs (miRNAs): ~22 nt. Post-transcriptional gene silencing.
      • OncomiRs (promote cancer): e.g., miR-21, miR-17-92 cluster.
      • Tumor suppressor miRNAs: e.g., let-7, miR-34a.
    • Long Non-Coding RNAs (lncRNAs): >200 nt. Diverse roles. E.g., HOTAIR, MALAT1. Epigenetic gene regulation mechanisms in cancer

⭐ Promoter hypermethylation of key tumor suppressor genes (e.g., CDKN2A (p16), MLH1, BRCA1) is a common epigenetic event driving carcinogenesis.

Immortality, Angiogenesis, Metastasis - Advanced Aggression

  • Immortality (Limitless Replication):
    • Telomerase (hTERT) activation: prevents telomere shortening.
    • Evasion of apoptosis: e.g., p53 mutations, ↑BCL-2 family proteins.
    • Bypass senescence signals.
  • Angiogenesis (New Blood Vessel Formation):
    • "Angiogenic switch": balance shifts to pro-angiogenic factors (VEGF, bFGF).
    • Hypoxia (via HIF-1α) is a potent inducer.
    • Tumor vessels are often abnormal: leaky, tortuous. Tumor angiogenesis showing irregular blood vessels
  • Metastasis (Distant Spread):
    • Sequential steps: local invasion → intravasation → systemic transport → extravasation → colonization.
    • Epithelial-Mesenchymal Transition (EMT): crucial for motility; ↓E-cadherin, ↑N-cadherin, ↑vimentin.
    • Matrix Metalloproteinases (MMPs) degrade ExtraCellular Matrix (ECM).

⭐ The "cadherin switch" (loss of E-cadherin, gain of N-cadherin) is a hallmark of EMT, facilitating tumor cell invasion.

High‑Yield Points - ⚡ Biggest Takeaways

  • Proto-oncogenes (e.g., RAS, MYC) and Tumor Suppressor Genes (e.g., TP53, RB) are critical.
  • TP53 ("guardian of the genome") is the most commonly mutated gene, vital for apoptosis.
  • RB gene controls the G1/S checkpoint; its loss drives proliferation.
  • RAS mutations cause constitutive activation of growth signaling pathways.
  • BRCA1/BRCA2 defects impair DNA repair, predisposing to breast and ovarian cancers.
  • Telomerase reactivation enables cancer cell immortality_._
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Molecular Basis of Cancer

Test your understanding with these related questions

The following gene mutation protects tumor cells from apoptosis:

1 of 5

Flashcards: Molecular Basis of Cancer

1/10

_____ is the most commonly mutated gene in sporadic breast carcinomas

TAP TO REVEAL ANSWER

_____ is the most commonly mutated gene in sporadic breast carcinomas

TP53

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free
Molecular Basis of Cancer - Free Indian Medical PG